LDHA and neoplasm: Preclinical investigations employing glycolytic pathway inhibitors-targeting glucose transporters (GLUTs), LDHA enzymatic activity, or lactate efflux mechanisms-have achieved significant suppression of tumor growth and chemotherapy desensitization, underscoring glycolysis inhibition as a promising therapeutic strategy (44–49).